Notably, the response rate with the combination of niraparib and pembrolizumab was 19% among patients with BRCA1/2 wild-type tumours, which compares favourably to previously reported ORR of less than 10% with either agent as a monotherapy in this population [88, 89]. The gene discussed is BRCA1; the disease is neoplasm.